Novel Peptide Shows Promise in Imaging and Treating Lymphoid Cancers

Researchers at the University of California, Davis Cancer Center have developed a novel peptide, LLP2A, that binds to the surface of leukemia and lymphoma cells with high affinity and specificity. The peptide demonstrates remarkable potential as a tool for imaging tumors and delivering anti-cancer drugs. In the Nature Chemical Biology paper, the researchers report that LLP2A binds specifically to malignant lymphocytes, not healthy ones, making it an ideal candidate for targeting lymphoid cancers.

Key Takeaways:

• LLP2A is a novel peptide that binds to the surface of leukemia and lymphoma cells with high affinity and specificity.
• The peptide is attracted specifically to malignant lymphocytes, not healthy ones, making it an ideal candidate for targeting lymphoid cancers.
• LLP2A has been shown to successfully image lymphoid tumors in living mice using a near-infrared scanner.
• The peptide has the potential to deliver radionuclides, cytotoxic agents, toxins, cytokines, and nanoparticles to lymphoid cancers.
• LLP2A binds to both B-cell and T-cell lymphoid cancer lines, and has low affinity for normal T or B lymphocytes.
• The peptide has lower uptake in the liver and spleen than current monoclonal antibodies for lymphoma treatment.
• The researchers are planning to test the peptide as a lymphoma imaging agent in patients, and have already begun testing it as a drug-delivery vehicle in mice.
• Experiments are underway to evaluate LLP2A in dogs with naturally occurring non-Hodgkin's lymphoma.

Statistics:

• 3 monoclonal antibodies (rituximab, ibritumomab tiuxetan, and tositumomab) have been approved by the FDA for the treatment of B-cell lymphoma.
• These antibodies have drawbacks, including binding to healthy lymphocytes along with malignant ones.
• LLP2A has been shown to have lower uptake in the liver and spleen than current monoclonal antibodies for lymphoma treatment.
• The researchers used the "one-bead-one-compound" method to synthesize millions of novel compounds in less than a week and analyze them in a few days.
• The peptide has the potential to target both B-cell and T-cell lymphoid cancers, making it a promising candidate for treating a range of lymphoid cancers.

Sources:

• Nature Chemical Biology
• University of California, Davis School of Veterinary Medicine
• Food and Drug Administration
• Health & Medicine Week editors
• NewsRx.com